Image
Unlock the Power of Novel Biologics Engineering with AI
Generative Biologics is an advanced, AI-powered platform for designing and optimizing different types of biologics including peptides, nanobodies, and antibodies tailored for specific targets.
Image
Generative Biologics Capabilities
  • Image
    Design binders for hard targets and desired epitopes in a de novo manner.
  • Image
    Generate novel, improved variants of your binder in 3D.
  • Image
    Optimize multiple properties of your candidates simultaneously.
  • Image
    Leverage your own data to train property- and project-specific predictive models.
  • Image
    Select candidates with desired properties for further development.
  • Image
    Built-in
    predictive models
    Use pre-trained models to predict and optimize developability properties.
Generate novel biologics
Biology42: Generative Biologics is designed for creation at speed and scale.
With over 10 generative and predictive models, supported by physics-based tools, our platform produces novel, diverse, and high-quality biologics, and can effectively target hard-to-drug proteins and specific epitopes. Our method enables the generation of binder candidates in less than 24 hours, accelerating discovery where it matters most.
Image
Image
Image
Image
Predict biomolecule properties
Identify the best candidates for further development by assessing their affinity and developability early in the discovery process.
Image
Image
Image
Image
Optimize your biologics
Simultaneously optimize multiple properties of your biomolecules. Use our optimization workflow to balance both affinity and developability, leveraging a combination of built-in and user-trained models for tailored results.
Image
Image
Image
Image
Train your own model
Build project-specific models using your own data to achieve high-accuracy predictions and let AI guide your experiments, reducing both time and cost. Our proprietary models are designed to work with specific biologic types, achieving higher precision compared to traditional LLMs.
Image
Image
Image
Image
Image
Flexible Business Models
Choose stand alone technology access or combine our software with Pharma.ai collaborations for a data-driven AI-partnership.
Image
Contact us
Please Note: If you are seeking information about participating in a clinical trial or treatment options, please consult your healthcare provider or primary care physician.